Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul;51(7):920-926.
doi: 10.1111/1346-8138.17170. Epub 2024 Mar 3.

Novel therapeutic targets in dermatomyositis

Christina Bax  1 , Carmel Aghdasi  1 , David Fiorentino  1
Affiliations
Review

Novel therapeutic targets in dermatomyositis

Christina Bax et al. J Dermatol. 2024 Jul.

Abstract

Dermatomyositis (DM) is a systemic autoimmune disease with variable clinical presentations, including inflammation in the skin, muscle, lungs, and/or joints. Current therapeutic strategies in DM typically include broad immunosuppression; however, the currently used modalities are not universally effective and are associated with various side effects, including risk of infection. There is currently a highly unmet need for more effective and well-tolerated therapies. Recent years have witnessed increased interest in pharmaceutical development of new therapeutic strategies for DM. This review aims to summarize the landscape of therapies that are currently being tested or planned in patients with DM. These therapies have a wide variety of immunological targets, including T cells, B cells, inflammatory signaling pathways, type I interferons, autoantibodies, and other targets.

Keywords: dermatomyositis; therapy.

PubMed Disclaimer

References

REFERENCES

    1. Caproni M, Torchia D, Cardinali C, Volpi W, Del Bianco E, D'Agata A, et al. Infiltrating cells, related cytokines and chemokine receptors in lesional skin of patients with dermatomyositis. Br J Dermatol. 2004;151:784–791.
    1. Huang P, Tang L, Zhang L, Ren Y, Peng H, Xiao Y, et al. Identification of biomarkers associated with CD4+ T‐cell infiltration with gene coexpression network in dermatomyositis. Front Immunol. 2022;13:854848.
    1. Patel J, Maddukuri S, Li Y, Bax C, Werth VP. Highly multiplexed mass cytometry identifies the immunophenotype in the skin of dermatomyositis. J Invest Dermatol. 2021;141:2151–2160.
    1. Wenzel J, Schmidt R, Proelss J, Zahn S, Bieber T, Tüting T. Type I interferon‐associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis. Clin Exp Dermatol. 2006;31:576–582.
    1. Nishimoto N, Kishimoto T, Yoshizaki K. Anti‐interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis. 2000;59(Suppl 1):i21.

MeSH terms

LinkOut - more resources